| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| J2326 |
Injection, nusinersen, 0.1 mg |
953 |
640 |
$80.91M |
| J2357 |
Injection, omalizumab, 5 mg |
8,421 |
6,608 |
$20.68M |
| Q9992 |
Injection, buprenorphine extended-release (sublocade), greater than 100 mg |
9,507 |
8,601 |
$15.04M |
| Q9991 |
Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg |
7,721 |
6,946 |
$12.00M |
| J0585 |
Injection, onabotulinumtoxina, 1 unit |
7,839 |
7,549 |
$8.14M |
| J3285 |
Injection, treprostinil, 1 mg |
594 |
429 |
$3.92M |
| J0517 |
Injection, benralizumab, 1 mg |
954 |
872 |
$3.70M |
| J1950 |
Injection, leuprolide acetate (for depot suspension), per 3.75 mg |
1,000 |
907 |
$3.68M |
| 90378 |
|
1,519 |
1,015 |
$3.21M |
| J0584 |
Injection, burosumab-twza 1 mg |
183 |
120 |
$3.15M |
| J7686 |
Treprostinil, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, 1.74 mg |
1,589 |
884 |
$2.82M |
| J1726 |
Injection, hydroxyprogesterone caproate, (makena), 10 mg |
1,312 |
999 |
$2.62M |
| J2182 |
Injection, mepolizumab, 1 mg |
708 |
611 |
$1.89M |
| J3490 |
Unclassified drugs |
125 |
116 |
$904K |
| J2323 |
Injection, natalizumab, 1 mg |
107 |
100 |
$831K |
| J7307 |
Etonogestrel (contraceptive) implant system, including implant and supplies |
981 |
808 |
$723K |
| J3241 |
Injection, teprotumumab-trbw, 10 mg |
14 |
12 |
$595K |
| J7318 |
Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg |
259 |
231 |
$277K |
| J0897 |
Injection, denosumab, 1 mg |
144 |
135 |
$163K |
| J7321 |
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose |
156 |
126 |
$107K |
| Q0513 |
Pharmacy dispensing fee for inhalation drug(s); per 30 days |
816 |
672 |
$103K |
| S9347 |
Home infusion therapy, uninterrupted, long-term, controlled rate intravenous or subcutaneous infusion therapy (e.g., epoprostenol); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem |
240 |
57 |
$60K |
| A4221 |
Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately) |
487 |
263 |
$42K |
| J7325 |
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg |
101 |
83 |
$32K |
| J1325 |
Injection, epoprostenol, 0.5 mg |
14 |
12 |
$23K |
| Q0512 |
Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period |
540 |
324 |
$2K |
| S5001 |
Prescription drug, brand name |
19 |
13 |
$870.17 |
| S9999 |
Sales tax |
455 |
402 |
$0.00 |